Life Science Investing Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia
Life Science Investing Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
West High Yield Resources Ltd. Corporate Update: Initial Reclamation Bond Posted, Permit Conditions Advancing, and Construction Pathway Strengthening for 2026
